EGMN -- Advisors to the Food and Drug Administration voted 20 to 2 that the risk-benefit profile of sodium oxybate did not support approval of the sedative-hypnotic drug as a treatment for fibromyalgia, citing concerns that included the lack of longterm data and the potential for illicit use of the drug.
